

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-15. (Canceled)

16. (2X Amended) A pharmaceutical composition comprising at least one HPV 16 L1ΔE7₁₋₅₅ fusion protein ~~from at least one L1 protein of one or more papillomaviruses and at least one C terminally deleted E7 protein, wherein about 38 to about 43 amino acids are deleted, of one or more papillomaviruses~~, wherein the fusion protein contains no papillomavirus-unspecific epitopes and wherein the pharmaceutical composition is capable of preventing or treating human papillomavirus (HPV)-specific tumour.

17. (Previously Presented) The pharmaceutical composition according to claim 16, wherein the tumour is a carcinoma of the larynx, cervix, penis, vulva or anus.

18. (Previously Presented) The pharmaceutical composition according to claim 16, wherein the pharmaceutical composition contains no adjuvant.

19. (Previously Presented) The pharmaceutical composition according to claim 16, wherein the pharmaceutical composition comprises suitable additives and/or excipients.

20. (Previously Presented) The pharmaceutical composition according to claim 19, wherein the additive or excipient is about 0.3 to about 4 M of a salt having a pH of about 7.3 to about 7.45.

21. (Previously Presented) The pharmaceutical composition according to claim 20, wherein the salt is an alkali metal or alkaline earth metal salt.

22. (Previously Presented) The pharmaceutical composition according to claim 20, wherein the pH is adjusted using a buffer.

23.-28. (Canceled)

29. (2X Amended) The pharmaceutical composition according to claim 16, wherein ~~font~~ the fusion protein is present in the form of a capsid and/or capsomer.

30.-31. (Canceled)

32. (Previously Presented) The pharmaceutical composition according to claim 20, wherein the additive or excipient is 0.4 to about 3 M of a salt having a pH of about 7.3 to about 7.45.

33. (Previously Presented) The pharmaceutical composition according to claim 20, wherein the additive or excipient is 0.5 to about 2 M of a salt having a pH of about 7.3 to about 7.45.

34. (Previously Presented) The pharmaceutical composition according to claim 20, wherein the additive or excipient is 1 to about 2 M of a salt having a pH of about 7.3 to about 7.45.

35. (2X Amended) The pharmaceutical composition according to claim 20, wherein the salt has a pH of 74 7.4.

36. (Previously Presented) The pharmaceutical composition according to claim 21, wherein the salt is a halide or a phosphate.

37. (Previously Presented) The pharmaceutical composition according to claim 21, wherein the salt is an alkali metal halide.

38. (Previously Presented) The pharmaceutical composition according to claim 21, wherein the salt is NaCl and/or KCl.

39. (Previously Presented) The pharmaceutical composition according to claim 22, wherein the pH is adjusted using a phosphate buffer, tris buffer, HEPES buffer or MOPS buffer.

40.-63. (Canceled)

64. (Amended) A method for producing a pharmaceutical composition comprising combining at least one ~~fusion protein from at least one L1 protein of one or more papillomaviruses and at least one C terminally deleted E7 protein, wherein about 38 to about 43 amino acids are deleted, of one or more papillomaviruses, wherein the fusion protein contains no papillomavirus unspecific epitopes~~ HPV 16 L1ΔE7₁₋₅₅ fusion protein, together with one or more pharmaceutically acceptable excipients to form a pharmaceutical composition, said pharmaceutical composition being capable of preventing or treating human papillomavirus (HPV)-specific tumour.

65. (Previously Presented) A method for preventing or treating human papillomavirus (HPV)-specific tumour, comprising administering to a subject in need thereof a pharmaceutical composition according to claim 16.

66. (Canceled)